Risk Factors Associated with Prostate Cancer
Globally prostate cancer is the second most familiar and fifth-most hostile neoplasm among male individuals. One of the emerging issues in men is prostate cancer. The Prostate is a ductal small walnut-shaped gland situated in men below the urinary bladder that produces the seminal fluid for sperms provision and transportation. The risk of emerging prostate cancer during the man’s lifetime is one out of seven. According to the epidemiological studies, different environmental and genetic factors are associated with the progression of abnormal prostate cell growth which ultimately causes the development of cancerous cells. The chances of prostate cancer occurrence are more in those patients with familial member’s history, and it can be more by two to three-folds associated with first-rank relatives to get prostate cancer. In the current review different risk factors which are associated with the development of prostate cancer, are discussed.
Keywords: Prostate cancer, Risk factors, Male, BRCA1, BRAC2.
2. Seisen T, Roupret M, Faix A, Droupy S. The prostate gland: a crossroad between the urinary and the seminal tracts. Progres en urologie: journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. 2012; 22:S2-6.
3. Cunha GR. Role of mesenchymal‐epithelial interactions in normal and abnormal development of the mammary gland and prostate. Cancer. 1994; 74(S3):1030-1044.
4. McNeal JE. Origin and evolution of benign prostatic enlargement. Investigative Urology. 1978; 15(4):340-345.
5. Hayward SW, Cunha GR, Dahiya R. Normal Development and Carcinogenesis of the Prostate: A Unifying Hypothesis a. Annals of the New York Academy of Sciences. 1996; 784(1):50-62.
6. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. 2015; 136(5):E359-E386.
7. Jain D, Chaudhary P, Varshney N, Janmeda P. Carcinogenic effects of N-nitroso compounds in the environment. Environment Conservation Journal. 2020; 21(3):25-41.
8. Favoriti P, Carbone G, Greco M, Pirozzi F, Pirozzi REM, Corcione F. Worldwide burden of colorectal cancer: a review. Updates in Surgery. 2016; 68(1):7-11.
9. Langan RC. Benign prostatic hyperplasia. Primary Care: Clinics in Office Practice. 2019; 46(2):223-232.
10. McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. The Journal of Urology. 2011; 185(5):1793-1803.
11. Habib A, Anjum KM, Ashraf Z, et al. Global Epidemiology of COVID-19 and the Risk of Second Wave. Journal of Drug Delivery and Therapeutics. 2021; 11(1):1-2.
12. Mahmood S, Qasmi G, Ahmed A, et al. Lifestyle factors associated with the risk of prostate cancer among Pakistani men. Journal of Ayub Medical College Abbottabad. 2012; 24(2):122-126.
13. Grasso CS, Wu Y-M, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012; 487(7406):239-243.
14. Helfand BT, Catalona WJ. The epidemiology and clinical implications of genetic variation in prostate cancer. The Urologic Clinics of North America. 2014; 41(2):277-297.
15. Ewing CM, Ray AM, Lange EM, et al. Germline mutations in HOXB13 and prostate-cancer risk. New England Journal of Medicine. 2012; 366(2):141-149.
16. Tomlins SA, Laxman B, Varambally S, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia. 2008; 10(2):177-IN179.
17. Carter BS, Ewing CM, Ward WS, et al. Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proceedings of the National Academy of Sciences. 1990; 87(22):8751-8755.
18. Xu J, Meyers D, Freije D, et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nature Genetics. 1998; 20(2):175-179.
19. Anderson DE, Badzioch MD. Breast cancer risks in relatives of male breast cancer patients. Journal of the National Cancer Institute. 1992; 84(14):1114-1117.
20. Schaid DJ. The complex genetic epidemiology of prostate cancer. Human Molecular Genetics. 2004; 13(suppl_1):R103-R121.
21. Huang H, Cai B. G84E mutation in HOXB13 is firmly associated with prostate cancer risk: a meta-analysis. Tumor Biology. 2014; 35(2):1177-1182.
22. Jain D, Chaudhary P, Kotnala A, Hossain R, Bisht K, Hossain MN. Hepatoprotective activity of medicinal plants: A mini review. Journal of Medicinal Plants. 2020; 8(5):183-188.
23. Dasgupta P, Baade PD, Aitken JF, Ralph N, Chambers SK, Dunn J. Geographical variations in prostate cancer outcomes: a systematic review of international evidence. Frontiers in Oncology. 2019; 9:238.
24. Rawla P. Epidemiology of prostate cancer. World journal of oncology. 2019; 10(2):63.
25. Grossman DC, Curry SJ, Owens DK, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. The journal of the American Medical Association. 2018; 319(18):1901-1913.
26. Howlader N, Noone A, Krapcho M, et al. Cronin KAe. SEER Cancer Statistics Review. 1975; 2010.
27. Habib A, Jaffar G, Khalid M. Letter to Editor: Challenges in the Development of Hepatitis C Vaccine. International Journal of Biomedical Investigation 2020; 3: 127.
28. DeSantis CE, Siegel RL, Sauer AG, et al. Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities. Cancer Journal for Clinicians. 2016; 66(4):290-308.
29. Barsouk A, Padala SA, Vakiti A, et al. Epidemiology, staging and management of prostate cancer. Medical Sciences. 2020; 8(3):28.
30. Rebbeck TR, Devesa SS, Chang B-L, et al. Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. Prostate Cancer. 2013; 2013.
31. Wu I, Modlin CS. Disparities in prostate cancer in African American men: what primary care physicians can do. Cleveland Clinic Journal of Medicine. 2012; 79(5):313-320.
32. Zeegers MP, Jellema A, Ostrer H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: A meta–analysis. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2003; 97(8):1894-1903.
33. Xu J, Meyers D, Freije D, et al. Evidence for a Prostate Cancer Susceptibility Locus on the X Chromosome. The Journal of Urology. 1999; 161(4):1386-1386.
34. Carpten J, Nupponen N, Isaacs S, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nature Genetics. 2002; 30(2):181-184.
35. Zhou A, Paranjape J, Brown TL, et al. Interferon action and apoptosis are defective in mice devoid of 2′, 5′‐oligoadenylate‐dependent RNase L. The EMBO journal. 1997;16(21):6355-6363.
36. Erkko H, Xia B, Nikkilä J, et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007; 446(7133):316-319.
37. Ferris-i-Tortajada J, Garcia-i-Castell J, Berbel-Tornero O, Ortega-Garcia J. Constitutional risk factors in prostate cancer. Actas Urológicas Españolas. 2011; 35(5):282-288.
38. Oh M, Alkhushaym N, Fallatah S, et al. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta‐analysis. The Prostate. 2019; 79(8):880-895.
39. Kibel AS, Schutte M, Kern SE, Isaacs WB, Bova GS. Identification of 12p as a region of frequent deletion in advanced prostate cancer. Cancer Research. 1998; 58(24):5652-5655.
40. Habib A, Razzak KSB, Imran M, Khalid B. Elimination of Hepatitis C Virus: A Goal of WHO. Vigyan Varta. 2020; 1:56-59.
41. Cuzick J, Thorat MA, Andriole G, et al. Prevention and early detection of prostate cancer. The Lancet Oncology. 2014; 15(11):484-492.
42. Ashworth A, Lord CJ. Synthetic lethal therapies for cancer: what’s next after PARP inhibitors? Nature Reviews Clinical Oncology. 2018; 15(9):564-576.
43. Kiciński M, Vangronsveld J, Nawrot TS. An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis. PloS One. 2011; 6(10):27130.
44. Kleihues P, Schauble B, zur Hausen A, Esteve J, Ohgaki H. Tumors associated with p53 germline mutations: a synopsis of 91 families. The American Journal of Pathology. 1997; 150(1):1.
45. Gennigens C, Menetrier-Caux C, Droz J. Insulin-Like Growth Factor (IGF) family and prostate cancer. Critical reviews in Oncology/Hematology. 2006; 58(2):124-145.
46. Liu X, Wang P, Fu J, et al. Two‐photon fluorescence real‐time imaging on the development of early mouse embryo by stages. Journal of Microscopy. 2011; 241(2):212-218.
47. Habib A, Ashraf Z, Principe U. Letter to Editor: Zoonotic Perspective of 2019 Novel Coronavirus Disease (COVID-19). International Journal of Pharmaceutics & Pharmacology. 2021; 5:149
48. Leongamornlert D, Mahmud N, Tymrakiewicz M, et al. Germline BRCA1 mutations increase prostate cancer risk. British Journal of Cancer. 2012; 106(10):1697-1701.
49. Price AJ, Allen NE, Appleby PN, et al. Insulin-like growth factor-I concentration and risk of prostate cancer: results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiology and Prevention Biomarkers. 2012; 21(9):1531-1541.
50. Machtens S, Baumann R, Hagemann J, et al. Long-term results of interstitial brachytherapy (LDR-Brachytherapy) in the treatment of patients with prostate cancer. World Journal of Urology. 2006; 24(3):289-295.
51. Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. Annals of African Medicine. 2019; 18(3):121.
52. Hsing AW, Chua Jr S, Gao Y-T, et al. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. Journal of the National Cancer Institute. 2001; 93(10):783-789.
53. Chang S, Hursting SD, Contois JH, et al. Leptin and prostate cancer. The Prostate. 2001; 46(1):62-67.
54. Aydogan F, Kalender E, Rifaioglu M, Sümbül A, Yengil E. The Effect of BMI and Visceral Fat Percentage on the Development of Bone Metastases in Prostate Cancer. Journal of Nuclear Medicine & Radiation. 2014; 5(193):2.
55. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. European Urology. 2013; 63(5):800-809.
56. Huncharek M, Haddock KS, Reid R, Kupelnick B. Smoking as a risk factor for prostate cancer: a meta-analysis of 24 prospective cohort studies. American Journal of Public Health. 2010; 100(4):693-701.
57. Li J, Thompson T, Joseph DA, Master VA. Association between smoking status, and free, total and percent free prostate specific antigen. The Journal of Urology. 2012; 187(4):1228-1233.
58. Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, Liauw SL. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. Journal of Clinical Oncology. 2010; 28(16):2653-2659.
59. Plaskon LA, Penson DF, Vaughan TL, Stanford JL. Cigarette smoking and risk of prostate cancer in middle-aged men. Cancer Epidemiology and Prevention Biomarkers. 2003; 12(7):604-609.
60. Kenfield SA, Stampfer MJ, Chan JM, Giovannucci E. Smoking and prostate cancer survival and recurrence. The journal of the American Medical Association. 2011; 305(24):2548-2555.
61. Hill P, Wynder E, Garbaczewski L, Garnes H, Walker A. Diet and urinary steroids in black and white North American men and black South African men. Cancer Research. 1979; 39(12):5101-5105.
62. Kolonel LN. Fat, meat, and prostate cancer. Epidemiologic Reviews. 2001; 23(1):72-81.
63. International WCRF. Diet, nutrition, physical activity and cancer: a global perspective: a summary of the Third Expert Report: World Cancer Research Fund International; 2018.
64. Hayes R, Pottern L, Strickler H, et al. Sexual behaviour, STDs and risks for prostate cancer. British Journal of Cancer. 2000; 82(3):718-725.
65. Adami H-O, Kuper H, Andersson S-O, Bergström R, Dillner J. Prostate cancer risk and serologic evidence of human papilloma virus infection: a population-based case-control study. Cancer Epidemiology and Prevention Biomarkers. 2003; 12(9):872-875.
66. Crum NF, Spencer CR, Amling CL. Prostate carcinoma among men with human immunodeficiency virus infection. Cancer. 2004; 101(2):294-299.
67. Dennis LK, Dawson DV. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology. 2002:72-79.
68. Holt SK, Salinas CA, Stanford JL. Vasectomy and the risk of prostate cancer. The Journal of Urology. 2008; 180(6):2565-2568.
69. Schwingl PJ, Meirik O, Kapp N, Farley TM. Prostate cancer and vasectomy: a hospital-based case–control study in China, Nepal and the Republic of Korea. Contraception. 2009; 79(5):363-368.
70. Dennis LK, Hayes RB. Alcohol and prostate cancer. Epidemiologic Reviews. 2001; 23(1):110-114.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).